[177Lu]Lu-PSMA-617 (Pluvicto™): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

被引：92
|
作者：
Hennrich, Ute [1 ]
Eder, Matthias [2 ,3 ,4 ]
机构：
[1] German Canc Res Ctr, Serv Unit Radiopharmaceut & Preclin Studies, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] German Canc Consortium DKTK, Div Radiopharmaceut Dev, Partner Site Freiburg, Freiburg, Germany
[3] German Canc Res Ctr, D-69120 Heidelberg, Germany
[4] Univ Freiburg, Univ Med Ctr Freiburg, Fac Med, Dept Nucl Med, D-79106 Freiburg, Germany
来源：
PHARMACEUTICALS | 2022年 / 15卷 / 10期
关键词：
Lu-177]Lu-PSMA-617; Pluvicto (TM); PSMA; prostate cancer; theranostics; radioligand therapy (RLT); GLUTAMATE CARBOXYPEPTIDASE-II; TARGETED RADIONUCLIDE THERAPY; UREA-BASED INHIBITORS; RADIOLIGAND THERAPY; MEMBRANE ANTIGEN; LU-177-PSMA-617; LU-177;
D O I：
10.3390/ph15101292
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
In March 2022, [Lu-177]Lu-PSMA-617 (Pluvicto (TM)) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [Lu-177]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [Lu-177]Lu-PSMA-617 was demonstrated.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Urinary excretion kinetics of [177Lu]Lu-PSMA-617
    de Bakker, Maarten
    Dominicus, Noa
    Meeuwis, Antoi
    Janssen, Marcel
    Konijnenberg, Mark W. W.
    Nagarajah, James
    Peters, Steffie M. B.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (12) : 3572 - 3575
  • [2] Urinary excretion kinetics of [177Lu]Lu-PSMA-617
    Maarten de Bakker
    Noa Dominicus
    Antoi Meeuwis
    Marcel Janssen
    Mark W. Konijnenberg
    James Nagarajah
    Steffie M. B. Peters
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 3572 - 3575
  • [3] Prognostic Tumor Markers In Men With Prostate Cancer Undergoing [177Lu]Lu-PSMA-617
    Yordanova, A.
    Linden, P.
    Hauser, S.
    Feldmann, G.
    Fimmers, R.
    Essler, M.
    Holdenrieder, S.
    Ahmadzadehfar, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S237 - S237
  • [4] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Anna Yordanova
    Paula Linden
    Stefan Hauser
    Michael Meisenheimer
    Stefan Kürpig
    Georg Feldmann
    Florian C. Gaertner
    Markus Essler
    Hojjat Ahmadzadehfar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080
  • [5] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Meisenheimer, Michael
    Kuerpig, Stefan
    Feldmann, Georg
    Gaertner, Florian C.
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1073 - 1080
  • [6] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    [J]. AKTUELLE UROLOGIE, 2023, 54 (04)
  • [7] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    [J]. LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [8] Re-challenge [177Lu]Lu-PSMA-617 in patients with advanced prostate cancer: outcome and safety
    Yordanova, Anna
    Essler, Markus
    Hauser, Stefan
    Feldmann, Georg
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [9] Administration of [177Lu] Lu-PSMA-617: Validation of a new method and first-experience
    Santos Virosta, M.
    Romero Zayas, I.
    Campos Anon, F.
    Paredes Barranco, P.
    Cordon Del Pozo, J.
    Fritsch Medina, A.
    Casanueva Eliceiry, S.
    Tormo Ratera, M.
    Quintero Martinez, K.
    Fuster Pelfort, D.
    Agusti, E.
    Rochera Alba, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S652 - S652
  • [10] [177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
    Mercolli, Lorenzo
    Mingels, Clemens
    Manzini, Giulia
    Cumming, Paul
    Zeimpekis, Konstantinos
    Xue, Song
    Alberts, Ian
    Uehlinger, Dominik
    Rominger, Axel
    Shi, Kuangyu
    Afshar-Oromieh, Ali
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (10) : 1570 - 1573
12345